Xcyte Therapies, Inc.

Seattle, WA 98134

SBIR Award Summary

Total Number of Awards 2
Total Value of Awards $1.17MM
First Award Date 09/24/99
Most Recent Award Date 09/10/03

Key Personnel

Last Name Name Awards Contact
Frohlich Mark W Frohlich 1
Bonyhadi Mark L Bonyhadi 1

2 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/10/03 - 08/31/05

DESCRIPTION (provided by applicant): Xcyte Therapies has developed a process ("Xcellerate") for the ex vivo activation and expansion of T cells using magnetic beads coated with antibodies to CD3 and CD28. Xcellerated T Cells from patients with CLL demonstrate an enhanced T cell repertoire, and the ability to induce the apoptosis of autologous tu...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/24/99 - 12/31/00

This study will determine the feasibility of using autologous activated T cells for the treatment of B-CLL. Xcyte s technology uses para-magnetic beads covalently coated with anti-CD3 and anti-CD28 anti-bodies, which makes the bead a potent polyclonal activator of T cells. Cells generated this way have been used at the University of Chicago to...